Senzime AB (publ) SEZI
Free
No email, no account, no signup.
General analysis — not personal advice.
Bull
Bear
Want to follow Senzime AB (publ)? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Exchange
NASDAQ
Type
Technology
Sector
Medical technology / patient monitoring
Price & valuation
Last close
SEK 4.03
1 week
+1.3 %
3 months
-10.2 %
12 months
-40.7 %
From 52w high
-40.8 %
From 52w low
+11.9 %
We're already tracking Senzime AB (publ) — here are the latest events we've registered
Recent News
- On August 5, 2026, Senzime announced that it was awarded an exclusive five-year national supply contract with U.S. Veterans Affairs through its partner TrillaMed. Additionally, on July 15, 2026, the company entered into a strategic development and commercialization partnership with Philips Medical Systems. Senzime subsequently released its Q2 2026 interim report on July 16, 2026.
What Firelda Watch includes for Senzime AB (publ)
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — AI roundup of the week's news
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Senzime AB (publ) will be delivered in the same format.
Want to follow Senzime AB (publ)? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.